Reliability of data collection for the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-center outcomes database: A methodological approach

被引：0
|
作者：
Kho, M. E.
Lepisto, E. M.
Niland, J. C.
terVeer, A.
LaCasce, A. S.
Friedberg, J. W.
Weeks, J. C.
机构：
[1] Dana Farber Canc Inst, Hamilton, ON, Canada
[2] Natl Comprehens Canc Network, Jenkintown, PA USA
[3] City Hope Comprehens Canc Ctr, Duarte, CA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6525
引用
收藏
页数：1
相关论文
共 39 条
  • [31] ONCOLOGY MEDICATION UTILIZATION BASED ON FEDERAL DRUG ADMINISTRATION (FDA) LABELING, NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) CLINICAL PRACTICE GUIDELINE (GL) RECOMMENDATIONS, AND EVIDENCE FOR PATIENTS WITH ADVANCED NON SMALL CELL LUNG CANCER (NSCLC): AN ANALYSIS FROM THE NCCN ONCOLOGY OUTCOMES DATABASE
    Lepisto, E. M.
    Vandergrift, J. L.
    Kalemkerian, G. P.
    Pisters, K. M.
    Zornosa, C.
    Rabin, M. S.
    Reid, M. E.
    Koczywas, M.
    Otterson, G. A.
    Ettinger, D. S.
    VALUE IN HEALTH, 2011, 14 (03) : A176 - A177
  • [32] A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, cytoxan, and rituxan (PCR) in the treatment or previously untreated or treated, stage III or IV, low-grade B-Cell non-Hodgkin's lymphoma (NHL) or bulky stage II lymphoma
    Mena, Raul R.
    Christiansen, Neil P.
    Markan, Yudhishtra
    Pandit, Lalita
    BLOOD, 2007, 110 (11) : 407A - 407A
  • [33] A multi-center phase II trial of CD-34+ peripheral blood stem cells (PBSC) and high dose cyclophosphamide (CY), VP-16, carboplatin (CB) and total body irradiation (TBI) for recurrent non-Hodgkin's lymphoma (NHL)
    Shea, T
    Perry, J
    Brown, R
    Yanovich, S
    Wiley, J
    Hurd, D
    DiPersio, J
    Pone, B
    Clapp, K
    Jacobs, C
    BLOOD, 1996, 88 (10) : 463 - 463
  • [34] Interim Report of Bendamustine Plus Rituximab As First-Line Induction Therapy with or without Lenalidomide Maintenance Therapy in Chinese Patients with Indolent Non-Hodgkin's Lymphoma or Elderly Mantle Cell Lymphoma: Data from a Multi-Center Prospective Trial
    Wang, Hui
    He, Qiang
    Zhao, Rongrong
    Xie, Linna
    Ma, Ji
    Liu, Cong
    Lu, Ke
    Wei, Haichen
    Liu, Dan
    Xing, Lijie
    Deng, Xiuzhi
    Sun, Zhongliang
    Chu, Xiaoxia
    Gao, Na
    Zhong, Yuping
    Sun, Yanhua
    Zhang, Haiyan
    Zhang, Hao
    Xu, Wenwei
    Li, Zengjun
    BLOOD, 2022, 140 : 11962 - 11963
  • [35] Updated Phase 1 Results from ZUMA-1: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 (Anti-CD19 CAR T Cells) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Locke, Frederick L.
    Neelapu, Sattva S.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Chavez, Julio C.
    Hosing, Chitra M.
    Ghobadi, Armin
    Budde, Lihua E.
    Bot, Adrian
    Rossi, John M.
    Sherman, Marika
    Navale, Lynn
    Elias, Meg
    Wiezorek, Jeff
    Go, William Y.
    MOLECULAR THERAPY, 2016, 24 : S294 - S294
  • [36] Ongoing complete remissions in phase 1 of ZUMA-1: a phase 1-2 multi-center study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with refractory aggressive B cell non-Hodgkin lymphoma (NHL)
    Locke, F. L.
    Neelapu, S. S.
    Bartlett, N. L.
    Siddiqi, T.
    Chavez, J. C.
    Hosing, C. M.
    Cashen, A.
    Budde, L. E.
    Sherman, M.
    Rossi, J. M.
    Navale, L.
    Jiang, Y.
    Aycock, J.
    Elias, M.
    Wiezorek, J.
    Go, W. Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Multi-center experience with novel transplant conditioning regimens that incorporate 90Y ibritumomab tiuxetan (Zevalin®) Radioimmunotherapy (RIT) for autologous and allogeneic stem cell transplantation in patients with poor-risk B-cell non-hodgkin's lymphoma (NHL):: Targeted intensification and elimination of total body irradiation
    Molina, A
    Nademanee, A
    Winter, JN
    Fung, HC
    Inwards, DJ
    Multani, P
    Khouri, I
    Raubitschek, A
    White, CA
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S48 - S48
  • [38] Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Locke, Frederick L.
    Neelapu, Sattva S.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Chavez, Julio C.
    Hosing, Chitra M.
    Ghobadi, Armin
    Budde, Lihua E.
    Navale, Lynn
    Aycock, Jeff S.
    Wiezorek, Jeff
    Go, William Y.
    BLOOD, 2015, 126 (23)
  • [39] Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
    Rossi, John M.
    Neelapu, Sattva S.
    Go, William Y.
    Shen, Yueh-wei
    Sherman, Marika
    Locke, Frederick L.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Navale, Lynn
    Elias, Meg
    Wiezorek, Jeff
    Bot, Adrian
    BLOOD, 2015, 126 (23)
1234